Navigation Links
Boehringer Ingelheim Presents New Phase II Data for Volasertib in Adult Patients with AML
Date:12/10/2012

RIDGEFIELD, Conn., Dec. 10, 2012 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today reported preliminary results from the randomized Phase II part of a Phase I/II study involving the company's investigational compound volasertib in newly diagnosed patients with acute myeloid leukemia (AML) considered ineligible for intensive remission induction therapy.  In this study, higher rates of objective response (primary endpoint) and a trend for longer median event free survival (EFS) (a secondary endpoint) were observed in patients treated with volasertib in combination with low-dose cytarabine (LDAC) compared to patients treated with LDAC alone. Presented at the 54th American Society of Hematology (ASH) annual meeting in Atlanta, Ga., these results support the initiation of a Phase III study of volasertib in combination with LDAC expected to start in early 2013. 

AML is one of the most common types of leukemia in adults.2  A common treatment approach is intensive chemotherapy to induce disease remission, followed by consolidation/maintenance chemotherapy.3,4  However, many patients over 65 years of age – whose prognosis is typically poor5 – are ineligible for this approach, which involves large doses of chemotherapy over short periods of time.3,4 

The open-label study enrolled 87 adult patients randomly assigned to receive either volasertib in combination with LDAC (n=42) or LDAC alone (n=45).   The primary endpoint was objective response (complete remission [CR] or CR with incomplete blood count recovery [CRi]).  Objective responses were observed in 31 percent of patients (13 of 42 patients) treated with the combination of volasertib plus LDAC compared with 13.3 percent of the patients (6 of 45 patients) treated with LDAC alone (odds ratio: 2.91; p = 0.0523).  The median (range) time to remission was 71 (2
'/>"/>

SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Boehringer Ingelheim Announces Equine Research Awards
2. Phase 2b Data of Boehringer Ingelheims Interferon-Free Hepatitis C Treatment Show Viral Cure Achieved in Up to 85% of Treatment-Naive Patients
3. Whistleblowers extraordinary efforts helped win $95 million settlement with Boehringer Ingelheim
4. Boehringer Ingelheim announces afatinib expanded access program (EAP) for patients with EGFR mutation-positive advanced NSCLC
5. Boehringer Ingelheim and Lilly introduce the My Well Planner Lifestyle Improvement Program for Adults with Type 2 Diabetes
6. Lilly and Boehringer Ingelheim Present Data at the 72nd American Diabetes Association Scientific Sessions® from Phase II Studies Comparing Investigational Novel Basal Insulin to Insulin Glargine
7. Boehringer Ingelheim Presents First Data for Tiotropium in Adolescents with Moderate Persistent Asthma
8. Results of Phase II Study of Boehringer Ingelheims Investigational Bronchodilator for COPD Presented at 2012 ATS International Conference
9. Boehringer Ingelheim to present pivotal Phase III results for afatinib in first-line treatment of EGFR mutation-positive NSCLC at ASCO 2012
10. New Data to be Presented at the Annual American Thoracic Society International Conference Demonstrates Depth of Boehringer Ingelheim Respiratory Research Pipeline
11. Boehringer Ingelheim Announces Launch of GLORIA™-AF Registry in Newly-Diagnosed Patients with Non-Valvular Atrial Fibrillation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... , Oct. 22, 2014  Cephasonics, a technology-innovation ... introduction of the cQUB™-1 (cQuest Ultrasound Box™-1), the first ... systems designed and manufactured by Cephasonics for purchase by ... model number. Cephasonics will be showcasing the cQUB-1 for ... this week in Chongqing, China ...
(Date:10/22/2014)... Vernak, RPh, of Vernak Farms Pharmacy in ... George Roentsch Scholarship by the Professional Compounding Centers of ... Houston during PCCA,s International Seminar, held October ... independent pharmacist and PCCA member who embodies the innovative ... well-known pharmacist in the compounding community. ...
(Date:10/22/2014)... 22, 2014 A new report ... (Product type, Form, End user, Application and Geography) - ... Research, Report, Opportunities, Segmentation and Forecast, 2013 - 2020", ... Based on key trends tracked, it is anticipated that ... billion by 2020, registering a CAGR of 6.2% from ...
Breaking Medicine Technology:Cephasonics Launches the cQUB-1, First Product in New Family of cQUB White-Label Ultrasound Systems Targeted at Medical Applications 2Cephasonics Launches the cQUB-1, First Product in New Family of cQUB White-Label Ultrasound Systems Targeted at Medical Applications 3PCCA Awards Charlene Vernak, RPh, the George Roentsch Scholarship 2Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 2Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 3Global Disposable Gloves Market Expected to Grow to $7.9 Billion by 2020 - Allied Market Research 4
... NASHVILLE, Tenn., March 5, 2012 /PRNewswire-iReach/ -- ... market products for "surgical GPS" of the abdomen, is ... as President and CEO, effective immediately. Mr. Cloar previously ... and Imaging division at Medtronic. Under his leadership, the ...
... Anthera Pharmaceuticals, Inc. (Nasdaq: ANTH ), ... including cardiovascular and autoimmune disorders, today announced that it ... directors. "Bogdan,s extensive global regulatory expertise ... perspective as we continue to navigate the evolving FDA ...
Cached Medicine Technology:Pathfinder Hires Medical Device Veteran as President and CEO 2Pathfinder Hires Medical Device Veteran as President and CEO 3Dr. Bogdan Dziurzynski Joins Anthera Pharmaceuticals Board of Directors 2Dr. Bogdan Dziurzynski Joins Anthera Pharmaceuticals Board of Directors 3
(Date:10/22/2014)... 2014 Richard Carlson, Managing Partner of ... with over 25 years experience. Mr. Carlson is ... areas related to EDI, B2B Commerce, RFID and Internet/Intranet ... Advisory Board member for Pharmaceutical Commerce Magazine and a ... Group is a management and technology consulting firm focused ...
(Date:10/22/2014)... HealthDay Reporter , TUESDAY, Oct. 21, 2014 ... may be showing a genetic propensity for obesity as toddlers, ... been linked to increased body fat, but the same genes ... the researchers said. At 1 year, kids with these ... 3, however, these genes were linked to excessive weight gain, ...
(Date:10/22/2014)... Oct. 21, 2014 (HealthDay News) -- Two sisters in ... heart damage. Ilina and Medha Krishen use electronic ... sounds of trouble in breathing patterns or heartbeats. ... in Michigan, wanted to find a way to detect ... pollutants. Using an electronic stethoscope, Ilina recorded one breath ...
(Date:10/22/2014)... By Maureen Salamon ... -- A crucial part of conventional in vitro fertilization (IVF) ... can instead take place in a device inside the vagina, ... Colombia contend that the device, called an INVOcell, might sharply ... could also make the technology more accessible to those who ...
(Date:10/22/2014)... Thompson HealthDay Reporter , MONDAY, ... Monday officially tightened guidelines for health workers treating Ebola patients, ... use of a respirator at all times. The U.S. ... tougher rules after two Dallas nurses contracted Ebola while caring ... Liberian national Thomas Eric Duncan. Nina Pham is currently being ...
Breaking Medicine News(10 mins):Health News:Rich Carlson and Marc Duey to Hold Workshop at CBI’s Specialty Pharmacy and Distribution Networks Conference 2Health News:Tall, Heavy 1-Year-Olds May Be at Risk for Obesity Later, Study Finds 2Health News:Teen Sisters Develop Ways to Measure Lung, Heart Damage 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 2Health News:Experimental Infertility Treatment Seems Effective, Cheaper 3Health News:Experimental Infertility Treatment Seems Effective, Cheaper 4Health News:CDC Tightens Rules on Caring for Ebola Patients 2Health News:CDC Tightens Rules on Caring for Ebola Patients 3
... INDIANAPOLIS, March 16 Hear Indiana proudly announces that ... be the lead supporter for the 6th Annual Talk ... hearing children in Indiana. "For more than 30 ... achieve their fullest potential as independent members of society," ...
... and Professional Certification ProgramsKERRY, Ireland and NEW ... Ireland-based provider of innovative learning solutions, today ... and certification programs for the American Institute ... Insurance Institute of America (the Institutes), leading ...
... March 16 OrbusNeich Medical, Inc. ("Orbus" or the ... medical devices for the treatment of vascular diseases, today ... Scientific Corporation ("BSC"). The lawsuit, filed in the ... Virginia, asserts claims against BSC for patent infringement, breach ...
... a novel genetic technology that covers up genetic errors, ... Health have developed a successful treatment for dogs with ... and ultimately fatal, muscle disease. , The technology, known ... as molecular "patches." These patches cover up mutant DNA ...
... Researchers announced today that a high-density genome wide analysis ... www.adni-info.org) is more than 95% complete and that data ... further analysis. , The ADNI data will be used ... the development of Alzheimer,s disease, which currently affects up ...
... Participation Raises Funds for Diabetes Charities MILPITAS, Calif., March 16 ... Life. Alive. At first glance, these words may ... millions of people with diabetes, they represent the many emotions ... words, and the individuals who wrote them, will be featured ...
Cached Medicine News:Health News:Peyton Manning Children's Hospital at St. Vincent Will Serve As Lead Sponsor of Hear Indiana's 6th Annual Talk Walk Run 2009 2Health News:Ireland's PulseLearning Inks Agreement With Leading U.S. Insurance Industry Association 2Health News:OrbusNeich Files Patent Infringement Lawsuit Against Boston Scientific 2Health News:OrbusNeich Files Patent Infringement Lawsuit Against Boston Scientific 3Health News:Researchers develop DNA 'patch' for canine form of muscular dystrophy 2Health News:Researchers develop DNA 'patch' for canine form of muscular dystrophy 3Health News:Alzheimer's Disease Neuroimaging Initiative announces completion of genome-wide analysis 2Health News:Alzheimer's Disease Neuroimaging Initiative announces completion of genome-wide analysis 3Health News:Photos: OneTouch(R) Features Five Participants From Global Diabetes Handprint Project in National Awareness and Fundraising Campaign 2Health News:Photos: OneTouch(R) Features Five Participants From Global Diabetes Handprint Project in National Awareness and Fundraising Campaign 3Health News:Photos: OneTouch(R) Features Five Participants From Global Diabetes Handprint Project in National Awareness and Fundraising Campaign 4
Shielding's new Surgical Drop Away / Flex Back Apron offers top of the shoulder velcro flaps for an adjustable fit. Features elastic back panels for added comfort and support. For quick removal apron...
Shielding's Standard Coat Apron with open back allows for freedom of movement, maximum flexibility and increased comfort....
This set includes 2 small, 1 medium, 1 large gonad shields and a belt. The shields and belt is an interchangeable system attached by velcro....
Lap pad used to protect pelvic regions...
Medicine Products: